[An estimation of individual radiosensitivity prostate malignant tumour cells using dynamic control of prostatic specific antigen level].
Individual radiosensitivity of prostate malignant tumor cells were estimated in blood of 122 patients in accordance with the level of prostate-specific antigen. Estimation has been performed in dynamics (before and after 3, 6, 12, 18, 24, 30 and 36 months) after radiation (external beam radiotherapy with total dose 70 Gy, brachytherapy with clinical dose 140-170 Gy) and hormone-radiation therapy. It was detected the differences of prostate tumors in the radioresistance. Levels of antigen at all times of detection in patients with relative radioresistant tumors (39 patients) were higher then in patients with radiosensitive tumors (81 patients). The number of persons with clinically unfavorable clinical prognosis in the group of patients with relative radioresistant tumors were registered 2 times more often then in group with radiosensitive timorous (35.9% vs. 16.0%). The ratio of patients with radiosensitive and relative radioresistant tumors depends on the method of treatment. It is supposed that after neoadjuvant hormone therapy tumour becomes more radiosensitive.
Minaeva
N G
NG
Parshkov
E M
EM
Golivets
T P
TP
Artamonova
Iu Z
IuZ
D000368:Aged; D006801:Humans; D008297:Male; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000532:radiotherapy*; D011836:Radiation Tolerance; D016896:Treatment Outcome
D017430:Prostate-Specific Antigen